REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAGM.L Regulatory News (AGM)

  • There is currently no data for AGM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Operational update

9 Oct 2019 14:00

RNS Number : 3273P
Applied Graphene Materials PLC
09 October 2019
 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

9 October 2019

Applied Graphene Materials plc

("Applied Graphene Materials", "AGM", the "Company" or "the Group")

Operational update

Applied Graphene Materials (LSE: AGM), the producer of specialty graphene materials and dispersions, provides an operational update ahead of the publication of its preliminary results on 16 October 2019 in respect of the year ended 31 July 2019.

AGM is to re-align its resources around its efficient dispersion and application technology to better support the product development of those customers that present the nearest-term revenue opportunities, in order to focus on growing sales. This re-alignment will reduce the Company's operating cost base, extend AGM's cash runway to at least two years and place the Company in a better position to deliver new products to the market place.

 

Background

 

This year, the Company has made important technical progress with its commercial partners and has strengthened its graphene dispersion product offerings which enable relative ease of use of graphene materials by customers. The Board believes that AGM remains extremely well positioned in its focused sectors as a result of its strong IP and compelling graphene application and integration technology. AGM's customer collaborations have continued to progress and gain momentum. However, it continues to take time to test products and build significant revenues. Further information on progress with customers will be included in the full year results.

 

Experience over recent years has clearly demonstrated that AGM's core expertise is in dispersion and application know-how to integrate the performance benefits of graphene nanoplatelets in an effective way in customer products. The Board has therefore decided to focus its resources and activities around meeting customer opportunities through the dispersion and end-use application of graphene as the best means of revenue growth.

As a result, today, the Board is entering a period of consultation with its employees with a view to implementing a re-alignment of its operations towards dispersion and application know-how and customer support. The Company will focus its resources on growing revenues from its significant pipeline of approximately 100 active engagements.

The Group will largely maintain its resources in its business development and technical teams to support customers in product development, rigorous testing and customer engagement whilst streamlining its manufacturing operations.

Financial impact (subject to consultation)

The cash operating cost base of the Company of £4.3m (unaudited) in the year to 31 July 2019 is expected to fall by circa £0.9m and £1.1m for the years ending 31 July 2020 and 2021, respectively. The cost of implementation of these changes is circa £0.2m. These actions will extend the Company's cash run-way to at least Q4 2021.

Unaudited draft preliminary results for the year ended 31 July 2019

As noted above, the Company will announce its results on 16 October 2019. Unaudited revenues and other income for the year were £0.12m with an unaudited EBITDA loss of £4.6m.

The Group had net cash of £6.1m as at 31 July 2019 and it received an R&D tax credit of £0.6m in August 2019.

Commenting on the proposed re-alignment, Adrian Potts, Chief Executive said:

 "Our absolute priority and focus remains to support our commercial partners in successfully incorporating graphene, achieving product launches and growing revenues. We have built an exceptional technology base around dispersion know-how and practical end-use of our products. The Board strongly believes that AGM is well placed in graphene and target market sectors and is confident that, with the reduced cost base and existing cash resources, the Company will have sufficient time to significantly grow revenues in the emerging graphene market.

I personally thank all of those employees that will be affected by this process for their hard work over the years and their valuable contribution to the Company."

 

For further information please contact:

Applied Graphene Materials

+44 (0) 1642 438 214

Adrian Potts, Chief Executive Officer 

David Blain, Chief Financial Officer

 

N+1 Singer

+44 (0) 207 496 3000

Richard Lindley / Justin McKeegan / Mia Gardner

 

Hudson Sandler

 +44 (0) 207 796 4133

Charlie Jack / Emily Dillon

 

 

Notes to Editors: 

About Applied Graphene Materials

Applied Graphene Materials works in partnership with its customers using its knowledge and expertise to provide bespoke graphene dispersions and formats to deliver enhancements and benefits for a wide range of applications. The Group's strategy is to target commercial application in three core markets: coatings, composites and polymers and functional fluids.

The Group has developed proprietary bottom-up processes capable of producing high purity graphene nanoplatelets using a continuous process. The manufacturing processes are based on sustainable, readily available raw materials and therefore do not rely on the supply of graphite, unlike most other graphene production techniques. Applied Graphene Materials owns the intellectual property and know-how behind these processes.

Applied Graphene Materials was founded by Professor Karl Coleman in 2010 with its operations and processes based on technology that he initially developed at Durham University. The Group was admitted to AIM in November 2013, raising £11 million, and is based at the Wilton Site on Teesside.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDLLFIFISLAIIA
Date   Source Headline
11th Jan 20163:36 pmRNSDirector/PDMR Shareholding
8th Jan 201612:13 pmRNSResult of Meeting
18th Dec 20157:00 amRNSPlacing and Open Offer
16th Nov 20157:00 amRNSFull Year Results
23rd Oct 20157:00 amRNSJoint Development Agreements and Collaborations
21st Sep 20155:19 pmRNSHolding(s) in Company
18th Sep 20157:00 amRNSPeriod end trading update
9th Jul 20157:00 amRNSIssue of share options to Directors
30th Jun 20153:36 pmRNSHolding(s) in Company
17th Jun 20157:00 amRNSFirst Patent Approval
19th May 20154:40 pmRNSSecond Price Monitoring Extn
19th May 20154:35 pmRNSPrice Monitoring Extension
14th May 20157:00 amRNSPositive results from independent oil trials
27th Apr 20159:21 amRNSHolding(s) in Company
22nd Apr 20154:44 pmRNSHolding(s) in Company
22nd Apr 20153:28 pmRNSHolding(s) in Company
21st Apr 20154:46 pmRNSHolding(s) in Company
17th Apr 20157:00 amRNSPositive results from independent coatings trials
2nd Apr 20159:46 amRNSHolding(s) in Company
1st Apr 20154:39 pmRNSHolding(s) in Company
25th Mar 20157:00 amRNSInterim Results
3rd Feb 20157:00 amRNSTrading Update
27th Jan 201511:25 amRNSIssue of equity and total voting rights
22nd Jan 20157:00 amRNSSenior Management Appointments
22nd Dec 20147:00 amRNSDirectorate Change
15th Dec 201411:36 amRNSResult of AGM
15th Dec 20147:00 amRNSAGM Statement
24th Nov 20147:00 amRNSPosting of Annual Report and Notice of AGM
17th Nov 20147:00 amRNSInvestor site visit
5th Nov 20147:00 amRNSAppointment of Non-Executive Director
5th Nov 20147:00 amRNSFull Year Results
5th Sep 20147:00 amRNSPre-close update
28th Jul 20147:00 amRNSIssue of share options to Directors
9th Jul 201410:17 amRNSGrant of Options to Directors
2nd Jul 20144:36 pmRNSHolding(s) in Company
23rd May 20143:08 pmRNSIssue of Share Options
30th Apr 20143:40 pmRNSReplacement - Holding(s) in Company
28th Apr 20148:50 amRNSHolding(s) in Company
1st Apr 20147:00 amRNSAppointment of Non Executive Director
1st Apr 20147:00 amRNSInterim Results
19th Mar 20147:00 amRNSNotice of Interim Results
18th Mar 201411:00 amRNSDirectorate Change
20th Jan 20144:39 pmRNSHolding(s) in Company
15th Jan 201410:59 amRNSIssue of Equity
27th Nov 20134:40 pmRNSSecond Price Monitoring Extn
27th Nov 20134:35 pmRNSPrice Monitoring Extension
26th Nov 20134:40 pmRNSSecond Price Monitoring Extn
26th Nov 20134:35 pmRNSPrice Monitoring Extension
22nd Nov 201312:39 pmRNSHolding(s) in Company
20th Nov 20137:00 amRNSAdmission and First Day of Dealings on AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.